Cyclacel Pharmaceuticals, Inc.·4

Dec 9, 9:00 PM ET

McBarron Paul 4

4 · Cyclacel Pharmaceuticals, Inc. · Filed Dec 9, 2019

Insider Transaction Report

Form 4
Period: 2019-12-05
McBarron Paul
DirectorEVP, Finance, CFO, COO
Transactions
  • Award

    Option

    2019-12-05+13,02213,022 total
    Exercise: $1.74Exp: 2027-12-29Common Stock (13,022 underlying)
  • Award

    Option

    2019-12-05+11,98011,980 total
    Exercise: $1.56Exp: 2028-02-22Common Stock (11,980 underlying)
Footnotes (2)
  • [F1]On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 13,022 shares.
  • [F2]On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 11,980 shares.

Documents

1 file
  • 4
    tm1924755d1_4.xmlPrimary

    OWNERSHIP DOCUMENT